Abstract 12015: Patients With Confirmed Statin Myalgia Do Not Exhibit Changes in Muscle Strength or Aerobic Performance
Background: There are observational reports of decreased muscle strength and aerobic performance in patients with statin myalgia, but no rigorous assessments of strength and aerobic performance in patients with confirmed statin myalgia. We examined the effect of simvastatin (SIMVA) 20 mg daily (mg/d) on muscle strength and aerobic performance in patients with confirmed statin myalgia.
Methods: Eighteen subjects (60 ± 10 years) whose statin myalgia was confirmed by their developing pain with SIMVA but not with placebo during an 8-week, double-blind crossover lead-in trial were randomized to SIMVA 20 mg/d for 8 weeks. Muscle pain (Brief Pain Inventory [BPI]), isometric handgrip strength, isometric and isokinetic arm and leg muscle strength, respiratory exchange ratio (RER) and maximal oxygen uptake (VO2max) were measured before and after SIMVA treatment.
Results: BPI pain severity (from 0.0 ± 0.0 to 1.7 ± 2.4 points) and interference (from 0.0 ± 0.0 to 1.4 ± 2.5 points) scores increased (both p < 0.01) with statin therapy. Muscle strength (all p >0.10) for 13 measured variables), RER (from 0.86 ± 0.08 to 0.87 ± 0.06; p = 0.92) and VO2max (from 24.5 ± 5.0 to 23.9 ± 5.1 mL/kg/min; p = 0.19) did not change with SIMVA.
Conclusions: Statin myalgia is not associated with decreases in muscle strength, resting fuel utilization, and aerobic performance.
Trial Registration: NCT01140308
Author Disclosures: A.L. Zaleski: None. B.A. Taylor: Consultant/Advisory Board; Modest; Amgen Pharmaceutical Safety Monitoring Board. L. Lorson: None. C.M. White: None. P.D. Thompson: Speakers Bureau; Significant; Dr. Thompson is a member of the speaker’s bureau for Merck & Company, Inc., Pfizer, Inc., Abbott Labs, Astra Zenica International, and Glaxo Smith Kline.. Consultant/Advisory Board; Significant; Dr. Paul Thompson is a consultant for Astra Zenica International, Merck & Company, Inc., The Schering-Plough Corporation, Roche, Esperion, Lupin Pharaceuticals, Pfizer, and Genomas.
- © 2014 by American Heart Association, Inc.